{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44","upperLimit":"71","value":"57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Overall Progression Free Survival at 2 years","dispersionType":"95% Confidence Interval","groups":[{"description":"Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine: Immunochemotherapy","id":"OG000","title":"Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 Years","title":"Progression Free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}